AN2 Therapeutics, Inc.(ANTX)

Biotechnology · Menlo Park, CA

$5.13-0.48 (-8.55%)

Delayed quote: Oct 6, 2026, 3:40 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:40:34.192Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:40:34.192Z.

Quote observation: 2026-10-06T19:40:12.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 184,780,924
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 44,318,000
TTM operating EBITDA · period ending 2026-06-30: -38,811,000

FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ANTX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ANTX Competitors' EV/EBITDA Ratio

ANTX

AN2 Therapeutics, Inc.

Current

Market Cap

$184.78M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELDN

Eledon Pharmaceuticals, Inc.

vs ANTX

Market Cap

$187.18M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTN

Canton Strategic Holdings Inc

vs ANTX

Market Cap

$182.41M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CMPX

Compass Therapeutics, Inc.

vs ANTX

Market Cap

$181.55M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORMP

Oramed Pharmaceuticals Inc.

vs ANTX

Market Cap

$180.31M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RXST

RxSight, Inc.

vs ANTX

Market Cap

$190.97M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ZNTL

Zentalis Pharmaceuticals, Inc.

vs ANTX

Market Cap

$191.14M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

YARW

Yarrow Bioscience Inc

vs ANTX

Market Cap

$175.95M

EV/EBITDA Ratio

N/A

TTM Avg

0.27x

3Y Avg

0.27x

5Y Avg

0.27x

PRQR

ProQR Therapeutics N.V.

vs ANTX

Market Cap

$174.81M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALEC

Alector, Inc.

vs ANTX

Market Cap

$198.73M

EV/EBITDA Ratio

N/A

TTM Avg

16.55x

3Y Avg

16.55x

5Y Avg

16.55x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
AN2 Therapeutics, Inc. (ANTX)	$184.78M	N/A	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$187.18M	N/A	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$182.41M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$181.55M	N/A	N/A	N/A	N/A
Oramed Pharmaceuticals Inc. (ORMP)vs ›	$180.31M	N/A	N/A	N/A	N/A
RxSight, Inc. (RXST)vs ›	$190.97M	N/A	N/A	N/A	N/A
Zentalis Pharmaceuticals, Inc. (ZNTL)vs ›	$191.14M	N/A	N/A	N/A	N/A
Yarrow Bioscience Inc (YARW)vs ›	$175.95M	N/A	0.27x	0.27x	0.27x
ProQR Therapeutics N.V. (PRQR)vs ›	$174.81M	N/A	N/A	N/A	N/A
Alector, Inc. (ALEC)vs ›	$198.73M	N/A	16.55x	16.55x	16.55x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics